Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.

Ariel Hammerman Candace Makeda Moore Enis Aboalhasan Joseph Azuri Ronen Arbel

Published in: Postgraduate medicine (2022)

Oral and subcutaneous semaglutide prescribed to prevent MACE in patients with T2DM provide similar value for money. The choice between both therapies should be guided mainly by patient preferences.

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
decision making
type diabetes
metabolic syndrome
skeletal muscle
glycemic control